Itrazay 100 Capsule contains Itraconazole 100 mg, a broad-spectrum triazole antifungal agent effective against a variety of fungal infections. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting cell membrane integrity and leading to fungal cell death. It is indicated for the treatment of systemic and superficial mycoses, including blastomycosis, histoplasmosis, aspergillosis, onychomycosis, and candidiasis. Itrazay 100 Capsule is administered orally and exhibits good bioavailability, with absorption enhanced when taken with food. The drug is extensively metabolized in the liver via the cytochrome P450 system, necessitating caution in patients with hepatic impairment and potential drug interactions. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain, as well as headache and dizziness. Serious adverse reactions are rare but may include hepatotoxicity and congestive heart failure in predisposed individuals. Itrazay 100 Capsule should be used under medical supervision, with dosage adjustments based on the severity of infection and patient response. Regular monitoring of liver function tests and potential drug interactions is recommended during therapy to ensure safety and efficacy.